GILEAD SCIENCES, INC.

GILD · Large cap · 0 articles

Financial highlights

Metric	FY 12/31/25	FY 12/31/24	FY 12/31/23	FY 12/31/22	FY 12/31/21
Income Statement
Revenue	$29.4B	$28.8B	$27.1B	$27.3B	$27.3B
Cost of revenue	$6.2B	$6.3B	$6.5B	$5.7B	$6.6B
Selling, general & administrative	$5.8B	$6.1B	$6.1B	$5.7B	$5.2B
Research and development	$5.8B	$5.9B	$5.7B	$5.0B	$4.6B
Operating income	$10.0B	$1.7B	$7.6B	$7.3B	$9.9B
Interest expense	$1.0B	$977.0M	$944.0M	$935.0M	$1.0B
Pretax income	$9.8B	$690.0M	$6.9B	$5.8B	$8.3B
Income tax expense	$1.3B	$211.0M	$1.2B	$1.2B	$2.1B
Net income	$8.5B	$480.0M	$5.7B	$4.6B	$6.2B
Balance Sheet
Cash and equivalents	—	—	—	$5.4B	$5.3B
Current assets	$18.3B	$19.2B	$16.1B	$14.4B	$14.8B
Total assets	$59.0B	$59.0B	$62.1B	$63.2B	$68.0B
Current liabilities	$11.8B	$12.0B	$11.3B	$11.2B	$11.6B
Stockholders' equity	$22.7B	$19.3B	$22.8B	$21.2B	$21.1B
Cash Flow Statement
Cash from operations	$10.0B	$10.8B	$8.0B	$9.1B	$11.4B
Depreciation and amortization	$370.0M	$381.0M	$354.0M	$323.0M	$329.0M
Stock-based compensation	$894.0M	$835.0M	$766.0M	$637.0M	$635.0M
Capital expenditure	$563.0M	$523.0M	$585.0M	$728.0M	$579.0M
Free cash flow	$9.5B	$10.3B	$7.4B	$8.3B	$10.8B
Dividends paid	$4.0B	$3.9B	$3.8B	$3.7B	$3.6B
Share repurchases	$1.9B	$1.1B	$1.0B	$1.4B	$546.0M
Impairments	$590.0M	$4.2B	$50.0M	$2.7B	$0

Shares outstanding 1.2B · Free float 74.8%

Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.